13F Holdings
中文EN

CTNM Contineum Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1855175 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-6.9%
TTM EPS YoY21.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.8%
ROA-28.3%
ROIC (approx.)-37.1%
Asset turnover—

Leverage & solvency

Liabilities / assets4.5%
Debt / equity0.00x
Current ratio31.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue—$0$50.00M
R&D expense$51.52M$38.42M$27.60M
SG&A expense$16.54M$12.47M$6.32M
Operating income-$68.06M-$50.89M$16.08M
Interest expense—$0$208,000
Pretax income-$60.14M-$42.26M$23.17M
Income tax$0$0$450,000
Net income-$59.98M-$42.26M$22.72M
EBITDA-$67.74M-$50.64M$16.27M
EPS (basic)-2.17-2.181.36
EPS (diluted)-2.17-2.180.08
Weighted avg. shares (diluted)27.70M19.35M3.40M
Balance sheet
Cash & equivalents$75.60M$21.94M$15.53M
Short-term investments$187.29M$182.82M$109.66M
Current assets$267.92M$206.39M$127.71M
PP&E, net$830,000$989,000$678,000
Total assets$276.64M$212.85M$130.39M
Current liabilities$9.74M$9.97M$5.48M
Total liabilities$15.65M$14.78M$5.70M
Shareholders' equity$260.99M$198.07M-$67.94M
Shares outstanding——2.35M
Cash flow statement
Operating cash flow-$55.31M-$32.84M$19.35M
Capital expenditure$231,000$514,000$414,000
Free cash flow-$55.54M-$33.36M$18.93M
Investing cash flow-$3.71M-$69.74M-$65.57M
Financing cash flow$112.69M$109.00M$56.18M
Depreciation & amortization$323,000$258,000$195,000
Stock-based compensation$10.04M$6.80M$2.22M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.